Treatment News : Long-Acting HIV Drugs Could Extend Lives of Low Adherers

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » November 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


November 6, 2013

Long-Acting HIV Drugs Could Extend Lives of Low Adherers

The current crop of long-acting antiretrovirals (ARVs) in development, which aim to require only monthly or quarterly dosing, could improve life expectancy among people with HIV, especially those with low adherence to daily regimens, reports. Investigators used a mathematical model to project the various impacts of long-acting ARVs in three scenarios: as the first-line therapy among treatment-naive people with HIV; as a second-line therapy for those who had failed their first-line treatment; and for those who have failed multiple regimens based on non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). The investigators presented their findings at the IDWeek 2013 conference in San Francisco.

The researchers found that long-acting ARVs would increase overall life expectancy by 0.5 to 0.6 years when compared with standard ARVs. Among those with low adherence to standard ARVs, treatment with long-acting drugs by comparison would increase life expectancy by two to three years.

Long-acting treatment was only cost effective among those who had failed multiple regimens, at $86,000 per quality adjusted life year. Giving the long-acting therapies to those with lowered adherence, however, increased its cost effectiveness in comparison with the cost-effectiveness for those with high adherence.

To read the IDWeek abstract, click here.

To read the HIVandHepatitis story, click here.

Search: Long-acting antiretrovirals, adherence, life expectancy, quality adjusted life years, cost-effectiveness, IDWeek.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 1 - 1 (of 1 total)    

Larry, Portland, 2013-11-07 16:03:01
$86,000 per year per med... no employer would ever hire somebody HIV+ with that kind of price tag. I take 4 meds, which would be $344,000 per year just for prescriptions.

comments 1 - 1 (of 1 total)    

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.